S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma (2014/12/6)|
|Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 (Ublituximab) in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety (2014/12/9)|
|TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib (Imbruvica(R)) for Patients With Select B-Cell Malignancies (2014/12/1)|
|TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference (2015/1/15)|
|TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors (2014/12/17)|
|Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) (2014/12/8)|
|TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference (2015/1/8)|
|TG Therapeutics, Inc. to Present at the 17th Annual BIO CEO & Investor Conference (2015/2/4)|
Click above to view more mutual fund data and stats for tgr - Tassal Group Ltd.